Ferreira A, García Rodriguez M C, Fontán G
Department of Laboratory Medicine, Hospital La Paz, Madrid, Spain.
Vox Sang. 1989;56(4):218-22. doi: 10.1111/j.1423-0410.1989.tb02032.x.
The levels of anti-IgA antibodies and the appearance of adverse reactions following gamma-globulin administration in 41 patients affected by primary antibody defects treated with intramuscular (IMGG) or intravenous gamma-globulin (IVGG), and 3 patients with the Wiskott-Aldrich syndrome (WAS) have been studied during a 31-month period. Anti-IgA antibodies were restricted to patients with circulating B lymphocytes and measurable amounts of IgA. The incidence of anti-IgA antibodies in the immunodeficient patients studied was 22.7%, and 2 of the 3 WAS patients also had high levels of anti-IgA antibodies. The presence of moderate levels of anti-IgA antibodies (up to 1/1,600) was not associated with adverse reactions. Our results indicate a significant relationship (p less than 0.02) between persistence of anti-IgA antibodies and IMGG administration.
在31个月的时间里，对41例接受肌肉注射（IMGG）或静脉注射丙种球蛋白（IVGG）治疗的原发性抗体缺陷患者以及3例维斯科特-奥尔德里奇综合征（WAS）患者注射丙种球蛋白后的抗IgA抗体水平及不良反应出现情况进行了研究。抗IgA抗体仅限于有循环B淋巴细胞且有可测量IgA量的患者。在所研究的免疫缺陷患者中，抗IgA抗体的发生率为22.7%，3例WAS患者中有2例也有高水平的抗IgA抗体。中等水平抗IgA抗体（高达1/1600）的存在与不良反应无关。我们的结果表明抗IgA抗体持续存在与肌肉注射丙种球蛋白之间存在显著关系（p<0.02）。
